Blog

Elad Sharon: Honored to receive a plaque for our team’s work getting the first immune checkpoint inhibitor approved in sarcoma!

Photo of Elad Sharon from American Association for Cancer Research

Feb 23, 2024, 17:26

Elad Sharon: Honored to receive a plaque for our team’s work getting the first immune checkpoint inhibitor approved in sarcoma!

Elad Sharon, Medical Oncologist at Dana-Farber Cancer Institute, made the following post on X:

“Honored to receive a plaque for our team’s work getting the first immune checkpoint inhibitor approved in sarcoma! Alveolar Soft Part Sarcoma is a rare cancer! Thanks for this NIH Director’s award! My last for work I did NCI CTEP Clinical Research! Thanks to National Institutes of Health, Genentech & FDA Oncology.”

Source: Elad Sharon/X

Alveolar Soft Part Sarcoma cancer Elad Sharon FDA Oncology Genentech immune checkpoint inhibitor National Institutes of Health NCI CTEP Clinical Research NIH NIH Director OncoDaily Oncology Research sarcoma

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage